Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis
Standard
Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. / Signorovitch, James; Diels, Joris; Van Sanden, Suzy; Schubert, Agata; Hassan, Fareen; Thilakarathne, Pushpike; Ozturk, Bulent; Barthelmes, Norma; Reich, Kristian.
in: J DERMATOL TREAT, Jahrgang 34, Nr. 1, 2169574, 12.2023.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis
AU - Signorovitch, James
AU - Diels, Joris
AU - Van Sanden, Suzy
AU - Schubert, Agata
AU - Hassan, Fareen
AU - Thilakarathne, Pushpike
AU - Ozturk, Bulent
AU - Barthelmes, Norma
AU - Reich, Kristian
PY - 2023/12
Y1 - 2023/12
N2 - BACKGROUND: Head-to-head comparisons through randomized controlled trials (RCTs) provide high-quality evidence to inform healthcare decisions. In their absence, indirect comparisons are often performed; however, evidence is limited on how valid matching-adjusted indirect comparison (MAIC)-based comparative efficacy estimates are vs. RCT-based estimates.OBJECTIVES: Compare MAIC and RCT results of guselkumab vs. secukinumab and ixekizumab to provide insight into the validity of results generated using MAIC methods.METHODS: Previously reported results from MAICs of guselkumab vs. secukinumab and ixekizumab were compared with results from ECLIPSE and IXORA-R RCTs based on risk differences between Psoriasis Area and Severity Index (PASI) 90 response rates.RESULTS: Risk difference (95% confidence interval) in PASI 90 response rates at week 48 for guselkumab vs. secukinumab was 14.4% (9.4%; 19.4%) in ECLIPSE and 9.4% (4.7%; 14.0%) in the MAIC. The risk difference at week 24 for guselkumab vs. ixekizumab was 0.0% (-5.4%; 5.4%) in IXORA-R and 0.7% (-5.1%; 6.4%) in the MAIC.CONCLUSIONS: Comparative efficacy results were consistent between MAICs and RCTs of guselkumab vs. secukinumab and ixekizumab. This analysis demonstrates that MAIC methods can provide valid relative treatment effect estimates when direct comparisons are lacking, particularly when trials with similar designs and patient populations inform the analysis.
AB - BACKGROUND: Head-to-head comparisons through randomized controlled trials (RCTs) provide high-quality evidence to inform healthcare decisions. In their absence, indirect comparisons are often performed; however, evidence is limited on how valid matching-adjusted indirect comparison (MAIC)-based comparative efficacy estimates are vs. RCT-based estimates.OBJECTIVES: Compare MAIC and RCT results of guselkumab vs. secukinumab and ixekizumab to provide insight into the validity of results generated using MAIC methods.METHODS: Previously reported results from MAICs of guselkumab vs. secukinumab and ixekizumab were compared with results from ECLIPSE and IXORA-R RCTs based on risk differences between Psoriasis Area and Severity Index (PASI) 90 response rates.RESULTS: Risk difference (95% confidence interval) in PASI 90 response rates at week 48 for guselkumab vs. secukinumab was 14.4% (9.4%; 19.4%) in ECLIPSE and 9.4% (4.7%; 14.0%) in the MAIC. The risk difference at week 24 for guselkumab vs. ixekizumab was 0.0% (-5.4%; 5.4%) in IXORA-R and 0.7% (-5.1%; 6.4%) in the MAIC.CONCLUSIONS: Comparative efficacy results were consistent between MAICs and RCTs of guselkumab vs. secukinumab and ixekizumab. This analysis demonstrates that MAIC methods can provide valid relative treatment effect estimates when direct comparisons are lacking, particularly when trials with similar designs and patient populations inform the analysis.
KW - Humans
KW - Mycobacterium avium Complex
KW - Treatment Outcome
KW - Psoriasis
KW - Severity of Illness Index
U2 - 10.1080/09546634.2023.2169574
DO - 10.1080/09546634.2023.2169574
M3 - SCORING: Journal article
C2 - 36724798
VL - 34
JO - J DERMATOL TREAT
JF - J DERMATOL TREAT
SN - 0954-6634
IS - 1
M1 - 2169574
ER -